Skip to main content
TipRanks
Go Ultimate75% OFF

Ardelyx (ARDX) AI Stock Analysis

1,930 Followers
ARDX

Ardelyx

(NASDAQ:ARDX)

Select Model
Rating:49Neutral
Price Target:$3.50â–²(12.18% Upside)
Action:reiterated
Date:11/05/26

The score is held back mainly by weak financial quality (continued losses, negative cash flow, and higher leverage) and a still-soft technical trend. Offsetting this, the latest earnings call was constructive with reaffirmed 2026 guidance, strong product revenue growth, and a stated path to profitability in 2027, but reimbursement and payer-related risks remain a notable overhang.

Positive Factors
Product Revenue GrowthStrong growth across both commercial products demonstrates expanding demand and improving market penetration. Continued prescription and writer gains, particularly for IBSRELA, can support operating leverage and provide a durable base for management’s reaffirmed 2026 revenue targets.
Negative Factors
Elevated LeverageRising leverage reduces financial flexibility while Ardelyx remains unprofitable. A higher debt burden can constrain investment in commercialization and trials, and it increases the consequences if revenue growth slows or the planned profitability milestone is delayed.

Ardelyx Key Performance Indicators (KPIs)

Revenue by SegmentSeparates revenue from product sales, licensing and collaboration payments, royalties, and milestones to show where the company’s money actually comes from. For Ardelyx, this reveals whether growth is driven by recurring commercial sales of its own drugs or by one‑time partner payments—steady product revenue points to sustainable commercial traction, while heavy reliance on milestones or licenses means earnings can be lumpy and more dependent on partner deals and development success.

$0.00$25.00M$50.00M$75.00M$100.00M$125.00MMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26Sep 26
Chart Insights

Ardelyx’s revenue is now clearly powered by product sales while licensing and collaborative revenues are episodic—those big license spikes are one‑offs, not a repeatable base. The commercial ramp (expanded sales force, IPN and reimbursement hires) explains recent product momentum and underpins management’s back‑half‑weighted guidance, but lowered near‑term IBSRELA guidance and payer step‑edits are a tangible risk; sustaining growth and reaching the 2027 profitability path depend on reimbursement wins and continued prescription momentum, not more licensing windfalls.

Data provided by:The Fly

Ardelyx (ARDX) vs. SPDR S&P 500 ETF (SPY)

-60%-40%-20%0%20%40%60%ARDX-42.44%SPY+13.11%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$799.36M
Dividend Yield
―
Average Volume (3M)
4.43M
Price to Earnings (P/E)
-13.9
Beta (1Y)
1.02
Revenue Growth
17.57%
EPS Growth
4.82%
Country
US
Employees
489
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Ardelyx Business Overview & Revenue Model

Company Description

Ardelyx, Inc. is a biopharmaceutical firm dedicated to the discovery, development, and commercialization of innovative medicines. The company primarily focuses on addressing gastrointestinal (GI) and cardiorenal conditions, serving patients both dome...

How the Company Makes Money

Ardelyx makes money primarily from sales of its commercial products and from collaboration-related income. Its key revenue stream is net product revenue generated by selling IBSRELA (for IBS-C) and XPHOZAH (for hyperphosphatemia in adults with CKD on...

Ardelyx Earnings Call Summary

Earnings Call Date:Nov 03, 2026(Q3-2026)|% Change Since:2.97%|Next Earnings Date:Feb 25, 2027
Earnings Call SentimentPositive

The call was predominantly positive, supported by 19% total product revenue growth, 23% IBSRELA growth, strong demand trends, reaffirmed 2026 guidance, improved net loss, $285.3 million of liquidity, and ahead-of-schedule enrollment in the ACCEL Phase III trial. The main challenges were persistent payer friction, complex XPHOZAH reimbursement dynamics, gross-to-net erosion, recent prescription-data volatility, and continued operating investments. Management remained confident in execution and the path to profitability in 2027.

Positive Updates

Total Product Revenue Growth
Third-quarter product revenue was $125.5 million, compared with $105.5 million in the same period last year, representing 19% year-over-year growth. IBSRELA and XPHOZAH generated over $125 million in combined revenue.

Negative Updates

Persistent Payer and Prior Authorization Friction
Payer friction remains a challenge for IBSRELA patients and physicians. Management said there is no single solution or magic bullet, that improvements will occur through meaningful steps over time, and that a dramatic inflection in prior authorization rates should not be anticipated.

Company Guidance

Ardelyx reaffirmed full year 2026 IBSRELA guidance of $350 million to $370 million, representing annual growth of more than 30% at the midpoint, and full year 2026 XPHOZAH revenue guidance of $110 million to $120 million; full year 2026 operating expenses are expected to be below $500 million, with profitability expected to occur in 2027, supported by a greater than 95% gross profit margin, while the company’s long-term view is achieving $1 billion in annual revenue for IBSRELA and it expects to report ACCEL top line results in the second half of 2027.

Ardelyx Financial Statement Overview

Summary

Strong revenue momentum and very high gross margins show improving fundamentals, but the company still has negative net income and negative operating/free cash flow. Rising leverage (elevated debt-to-equity) adds financial risk if the path to profitability is delayed.

Income Statement

58Neutral

Balance Sheet

46Neutral

Cash Flow

41Neutral
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue468.22M407.32M333.62M124.46M52.16M10.10M
Gross Profit441.34M364.72M283.06M106.66M48.04M9.10M
EBITDA-28.70M-29.17M-16.71M-55.35M-60.98M-150.85M
Net Income-55.47M-61.60M-39.14M-66.07M-67.21M-158.16M
Balance Sheet
Total Assets587.52M501.60M435.75M297.58M190.07M149.91M
Cash, Cash Equivalents and Short-Term Investments285.34M264.69M250.10M184.30M123.91M116.69M
Total Debt256.34M211.59M153.44M55.98M36.46M45.50M
Total Liabilities423.48M334.65M262.46M130.76M91.74M67.30M
Stockholders Equity164.05M166.95M173.29M166.82M98.33M82.62M
Cash Flow
Free Cash Flow-15.96M-43.98M-45.82M-90.06M-70.10M-154.42M
Operating Cash Flow-15.51M-42.48M-44.81M-89.72M-70.04M-152.55M
Investing Cash Flow-37.56M-8.96M-18.32M-131.25M18.41M50.95M
Financing Cash Flow56.68M54.51M106.59M146.29M75.34M83.00M

Ardelyx Technical Analysis

Technical Analysis SentimentPositive
Last Price3.12

Price Trends

50DMA3.25Negative
100DMA3.92Negative
200DMA5.06Negative

Market Momentum

MACD-0.05Negative
RSI51.97Neutral
STOCH55.93Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARDX, the sentiment is Positive. The current price of 3.12 is above the 20-day moving average (MA) of 3.07, below the 50-day MA of 3.25, and below the 200-day MA of 5.06, indicating a neutral trend. The MACD of -0.05 indicates Negative momentum. The RSI at 51.97 is Neutral, neither overbought nor oversold. The STOCH value of 55.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ARDX.

Ardelyx Risk Analysis

Ardelyx disclosed 53 risk factors in its most recent earnings report. Ardelyx reported the most risks in the "Legal & Regulatory" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

3 New Risks
1.Our business may be affected by the evolving regulatory framework for AI TechnologiesQ3, 2026
2.Our business may be affected by the evolving regulatory framework for AI TechnologiesQ2, 2026
3.Our future business prospects may depend on our ability, alone or through our current or future collaborations, to successfully develop, gain regulatory approval of and commercialize our current and future product candidates.Q4, 2025

Ardelyx Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

ARDX against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
CRMDCRMD74Outperform$371.44M5.6314.48%―92.48%-64.25%
PHATPHAT59Neutral$430.85M-5.1429.66%―86.75%72.98%
DMACDMAC53Neutral$463.49M-11.30-94.47%――-4.56%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
ARDXARDX49Neutral$799.36M-13.89-35.30%―17.57%4.82%
LXRXLXRX46Neutral$765.80M-11.84-38.44%―-45.62%21.16%
ENTAENTA41Neutral$253.10M-3.50-64.32%―-3.56%38.76%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%ARDXCRMDLXRXENTADMACPHATDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
ARDX and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
ARDXArdelyx Inc3.12-2.43-43.78%
CRMDCormedix Inc.4.50-5.22-53.70%
LXRXLexicon Pharmaceuticals1.720.4030.30%
ENTAEnanta Pharmaceuticals8.23-3.90-32.15%
DMACDiamedica Therapeutics8.591.3718.98%
PHATPhathom Pharmaceuticals, Inc.5.30-9.06-63.09%

Ardelyx Corporate Events

Business Operations and StrategyFinancial Disclosures

Ardelyx Reports Third-Quarter Revenue Growth and Narrowed Loss

Positive
Nov 3, 2026

On November 3, 2026, Ardelyx reported third-quarter product revenue of $125.5 million, up 19% year over year. IBSRELA revenue rose 23% to $96.3 million, while XPHOZAH revenue increased 7% to $29.2 million, reflecting higher demand, writers and prescr...

Executive/Board Changes

Ardelyx Chief Commercial Officer Announces Upcoming Resignation

Neutral
Aug 17, 2026

On August 11, 2026, Ardelyx, Inc. announced that Chief Commercial Officer Eric Foster had notified the company of his decision to resign, effective August 28, 2026. The departure, which was to allow Foster to pursue a new role at a pre-commercial com...

Business Operations and StrategyFinancial DisclosuresLegal ProceedingsPrivate Placements and Financing

Ardelyx Updates Outlook Amid Q2 Growth and Recalibration

Neutral
Aug 6, 2026

Ardelyx reported that in the second quarter ended June 30, 2026, total product revenue rose 31% year over year to $118.1 million, driven by IBSRELA sales of $86.2 million and XPHOZAH sales of $31.9 million, while cash and investments reached $281.8 m...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 05, 2026